title: [Follow-up of HIV carriers by a laboratory method. I: Virus isolation is useful for prognostication of the onset of symptoms].
abstract: We followed 54 HIV-1 carriers (44 asymptomatic carriers and 10 AIDS patients) by virus isolation and immunological examination and evaluated their usefulness for prognostication of the onset of symptoms. From 37 carriers (27 asymptomatic carriers and 10 symptomatic), 132 HIV-1 strains were isolated; the virus isolation rate was 60% in the asymptomatic carriers (AC) but 100% in the symptomatic. In the AC, the isolation rate was 54.5% in the group showing stable in the CD4+ level but 95.5% in the group showing a decrease in the CD4+ level. With progression of the disease, the culture time required for virus isolation was shortened, and the percentage of isolates showing infectivity to the T-cell line (MT-4 cells) increased. These findings suggest that the virus in the body is changed with progression of the disease to that showing rapid replication, T-cell tropic, and high pathogenicity. Indeed, progression of the disease was observed in all carriers in whom a highly pathogenic virus was detected; some developed the disease within 1 year, some showed temporary recovery in the CD4+ level after AZT administration followed by progression to ARC, and others showed a rapid decrease in the CD4+ level. In contrast, in carriers with only slightly pathogenic virus, the CD4+ level was maintained for a long period. These results suggest that the detection of a highly pathogenic virus is one of the most reliable marker for the prognostication of the onset of the disease. The detection of HIV-1 antigen in the plasma and a decrease in the gag antibody were also associated with the progression of the disease. However, the reliability of these markers seems to be lower than that of virus isolation.
authors.affiliation: Osaka Prefectural Institute of Public Health, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Otake
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Morimoto
authors.forename: T
authors.initials: T
authors.lastname: Kawahata
authors.forename: N
authors.initials: N
authors.lastname: Ueba
authors.forename: S
authors.initials: S
authors.lastname: Okubo
authors.forename: K
authors.initials: K
authors.lastname: Yasunaga
authors.forename: N
authors.initials: N
authors.lastname: Nagao
authors.forename: Y
authors.initials: Y
authors.lastname: Okubo
authors.forename: K
authors.initials: K
authors.lastname: Sano
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: M
authors.initials: M
authors.lastname: Nakai
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000821:virology*; D015415:Biomarkers; D015704:CD4 Antigens / Q000097:blood; D002353:Carrier State / Q000175:diagnosis / Q000821:virology*; D005500:Follow-Up Studies; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D011379:Prognosis
chemical_list: D015415:Biomarkers; D015704:CD4 Antigens